IOL Chemicals and Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 1/6
De winst van IOL Chemicals and Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -29%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 13.4%. De inkomsten zijn groeide met een gemiddeld percentage van 3.3% per jaar. Het rendement op het eigen vermogen IOL Chemicals and Pharmaceuticals bedraagt 6% en de nettomarge bedraagt 4.9%.
Belangrijke informatie
-29.0%
Groei van de winst
-29.7%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 3.3% |
| Rendement op eigen vermogen | 6.0% |
| Nettomarge | 4.9% |
| Volgende winstupdate | 19 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price
Sep 11
Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?
Jun 12Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Aug 30IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet
May 18IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00
Feb 10Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Jun 07Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
May 07Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?
May 04Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?
Mar 13Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Feb 23Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?
Feb 08IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 27How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?
Jan 15Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Jan 02
Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return
Dec 21Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?
Dec 09These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well
Nov 24IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend
Nov 12Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?
Nov 09Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?
Oct 27Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay
Oct 09Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Sep 18Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today
Sep 03Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely
Aug 16IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Seems To Use Debt Rather Sparingly
Jul 27Opbrengsten en kosten
Hoe IOL Chemicals and Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 20,521 | 998 | 2,114 | 0 |
| 30 Jun 24 | 20,720 | 1,185 | 2,017 | 0 |
| 31 Mar 24 | 21,328 | 1,344 | 2,027 | 0 |
| 31 Dec 23 | 22,161 | 1,716 | 1,938 | 0 |
| 30 Sep 23 | 22,192 | 1,723 | 1,873 | 0 |
| 30 Jun 23 | 22,153 | 1,503 | 1,787 | 0 |
| 31 Mar 23 | 22,171 | 1,391 | 1,686 | 0 |
| 31 Dec 22 | 22,024 | 1,041 | 1,633 | 0 |
| 30 Sep 22 | 22,341 | 1,204 | 1,567 | 0 |
| 30 Jun 22 | 22,305 | 1,353 | 1,518 | 0 |
| 31 Mar 22 | 21,840 | 1,677 | 1,415 | 0 |
| 31 Dec 21 | 20,719 | 2,132 | 1,350 | 0 |
| 30 Sep 21 | 20,298 | 2,879 | 1,280 | 0 |
| 30 Jun 21 | 20,254 | 3,840 | 1,251 | 0 |
| 31 Mar 21 | 19,670 | 4,446 | 1,157 | 0 |
| 31 Dec 20 | 19,481 | 4,596 | 1,104 | 0 |
| 30 Sep 20 | 19,463 | 4,428 | 1,062 | 0 |
| 30 Jun 20 | 18,618 | 4,035 | 975 | 0 |
| 31 Mar 20 | 18,945 | 3,613 | 974 | 0 |
| 31 Dec 19 | 18,753 | 3,727 | 923 | 0 |
| 30 Sep 19 | 18,423 | 3,569 | 904 | 0 |
| 30 Jun 19 | 18,163 | 3,076 | 855 | 0 |
| 31 Mar 19 | 16,853 | 2,367 | 794 | 0 |
| 31 Dec 18 | 15,506 | 1,465 | 736 | 0 |
| 30 Sep 18 | 13,350 | 731 | 657 | 0 |
| 30 Jun 18 | 11,298 | 391 | 605 | 0 |
| 31 Mar 18 | 9,833 | 277 | 562 | 0 |
| 31 Dec 17 | 8,891 | 178 | 526 | 0 |
| 30 Sep 17 | 8,094 | 100 | 495 | 0 |
| 30 Jun 17 | 8,265 | 65 | 26 | 0 |
| 31 Mar 17 | 7,107 | 47 | 433 | 0 |
| 31 Dec 16 | 6,595 | 39 | 436 | 0 |
| 30 Sep 16 | 6,197 | -74 | 407 | 0 |
| 30 Jun 16 | 6,055 | -214 | 382 | 0 |
| 31 Mar 16 | 5,804 | -400 | 352 | 0 |
| 31 Dec 15 | 5,131 | -692 | 386 | 0 |
| 30 Sep 15 | 4,377 | -890 | 363 | 0 |
| 30 Jun 15 | 4,008 | -858 | 261 | 0 |
| 31 Mar 15 | 3,847 | -667 | 248 | 0 |
| 31 Dec 14 | 4,405 | -378 | 277 | 0 |
| 30 Sep 14 | 5,115 | -71 | 281 | 0 |
| 30 Jun 14 | 5,452 | 37 | 271 | 0 |
| 31 Mar 14 | 5,635 | 33 | 398 | 0 |
| 31 Dec 13 | 5,684 | 26 | 267 | 0 |
Kwaliteitswinsten: IOLCP heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (4.9%) IOLCP } zijn lager dan vorig jaar (7.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van IOLCP is de afgelopen 5 jaar met 29% per jaar gedaald.
Versnelling van de groei: De winstgroei IOLCP is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: IOLCP had het afgelopen jaar een negatieve winstgroei ( -42.1% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 19.2% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 6% ) van IOLCP wordt als laag beschouwd.